Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Recurrent respiratory papillomatosis (RRP) is classically described as a benign neoplasm of the larynx. Nevertheless, transformation to dysplasia and invasive carcinoma can occur. Sarcoma of the larynx is rare. Here, we present a case of sarcoma in a patient repeatedly treated for RRP.
Case Report: We report a case of a 73- year old Caucasian male diagnosed with adult-onset recurrent respiratory papillomatosis (AORRP) at the age of 63y. o. During the previous 10 years, he underwent multiple surgeries. In the last therapeutic intervention, he was treated with laser excision of the papilloma and topical mitomycin application. Two months after treatment, papilloma recurred and sarcoma was diagnosed.
Conclusions: RRP is a benign lesion. Affected patients usually require multiple interventions. It rarely degenerates to malignancy. Sarcoma in the larynx in the presence of RRP is a rare case. Extended surgical removal remains the treatment of choice. Adjuvant therapies consist of chemotherapy and radiation and are reserved for unresectable or recurrent cases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801009 | PMC |
| http://dx.doi.org/10.22038/IJORL.2021.57188.2967 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving oncological outcomes for pelvic bone sarcomas: Is it possible?
Eur J Surg Oncol
August 2025
Royal Orthopaedic Hospital, Birmingham, United Kingdom.
Introduction: Pelvic bone sarcomas are rare, heterogeneous malignancies that present significant diagnostic and therapeutic challenges. Despite advances in imaging, surgical navigation, and multidisciplinary care, it remains unclear whether these innovations have improved outcomes across all histiotypes.
Material And Methods: We conducted a retrospective cohort study of 475 patients surgically treated for primary pelvic bone sarcomas between 2003 and 2022.
Retrospective Study of Pediatric Sinonasal Tumors in a Tertiary Hospital Setting.
Am J Case Rep
September 2025
Department of Otolaryngology - Head and Neck Surgery, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
BACKGROUND Pediatric sinonasal tumors are rare, accounting for about 4% of all pediatric head and neck neoplasms. Due to their nonspecific symptoms such as nasal obstruction, epistaxis, and facial pain, these tumors often present diagnostic challenges and lead to delays in managment. Early and accurate diagnosis is crucial to optimize clinical outcomes.
View Article and Find Full Text PDFRib Ewing Sarcomas in Children and Young Adults: A Large National Retrospective Series.
Pediatr Blood Cancer
September 2025
Department of Radiation Oncology, Centre Léon Bérard, Lyon, France.
Background And Purpose: Ewing sarcoma (ES) is the most prevalent malignant thoracic tumor in childhood and young adults. This study reports the outcome of a national cohort treated in an international prospective trial for a localized rib ES, with a long follow-up.
Material And Methods: All the patients treated in a prospective trial (December 1999-April 2013) were included.
Relapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (EpSSG).
Br J Cancer
September 2025
Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
At least one-third of patients with localized rhabdomyosarcoma (RMS) and 60-70% of patients with metastatic RMS experience progressive disease or relapse. Following relapse, outcomes generally remain poor with limited treatment options and a high risk of subsequent recurrence. Optimal treatment requires a multidisciplinary approach incorporating chemotherapy with local control.
View Article and Find Full Text PDFHigh transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.
J Immunother Cancer
September 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Response to immune checkpoint inhibition (ICI) in sarcomas is overall low and heterogeneous. Understanding determinants of ICI outcomes may improve efficacy and patient selection. Thus, we investigated whether the expression of transposable elements (TEs), which are epigenetically silenced and can stimulate antitumor immunity, influence ICI outcomes and immune infiltrates in common sarcoma subtypes.
View Article and Find Full Text PDF